Replacing clinic-based tests with home-use tests may increase HIV prevalence among seattle men who have sex with men: Evidence from a mathematical model

Sexually Transmitted Diseases

Volumn 41, Issue 1, 2014, Pages 2-9

  Katz, David A ^a   Cassels, Susan L ^b,c   Stekler, Joanne D ^a,b,d  

^a Departments of Laboratory Medicine   (United States)

^b Health Services and Epidemiology   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d HIV/STD Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN ANTIBODY COMPLEX; ARTICLE; CLINIC BASED TEST; EPIDEMIC; HIV TEST; HOME USE TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MEN WHO HAVE SEX WITH MEN; NUCLEIC ACID AMPLIFICATION; TASK PERFORMANCE; UNITED STATES; VIRUS TRANSMISSION;

ADULT; AMBULATORY CARE FACILITIES; CONDOMS; FALSE NEGATIVE REACTIONS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH SERVICES ACCESSIBILITY; HIV SEROPOSITIVITY; HOMOSEXUALITY, MALE; HUMANS; MALE; MASS SCREENING; MODELS, THEORETICAL; NUCLEIC ACID AMPLIFICATION TECHNIQUES; PREVALENCE; REAGENT KITS, DIAGNOSTIC; RISK ASSESSMENT; SELF CARE; SEXUAL BEHAVIOR; WASHINGTON;

EID: 84891631764     PISSN: 01485717     EISSN: 15374521     Source Type: Journal    
DOI: 10.1097/OLQ.0000000000000046     Document Type: Article

References (34)

1. Spielberg F, Levine RO, Weaver M. Self-testing for HIV: A new option for HIV prevention? Lancet Infect Dis 2004; 4:640-646.
2. Safety and effectiveness of the proposed OraQuick\ In-Home HIV Test. U.S. Food and Drug Administration Blood Products Advisory Committee: 102nd Meeting; Gaithersburg, MD; 2012.
3. Campbell S, Klein R. Home testing to detect human immunodeficiency virus: Boon or bane? J Clin Microbiol 2006; 44:3473-3476.
4. Walensky RP, Bassett IV. HIV self-testing and the missing linkage. PLoS Med 2011; 8:e1001101.
5. Proposed studies to support the approval of over-the-counter (OTC) home use HIV test kits. U.S. Food and Drug Administration Blood Products Advisory Committee: 86th Meeting; Gaithersburg, MD; 2006.
6. U.S. Food and Drug Administration. OraQuick\ In-Home HIV Test: Summary of Safety and Effectiveness. Available at: http://www.fda.gov/downloads/ BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/ PremarketApprovalsPMAs/UCM312534.pdf. Accessed December 17, 2012.
7. Stekler JD, Swenson PD, Coombs RW, et al. HIV testing in a highincidence population: Is antibody testing alone good enough? Clin Infect Dis 2009; 49:444-453.
8. Cassels S, Menza TW, Goodreau SM, et al. HIV serosorting as a harm reduction strategy: Evidence from Seattle, Washington. AIDS 2009; 23:2497-2506.
9. Brewer DD, Golden MR, Handsfield HH. Unsafe sexual behavior and correlates of risk in a probability sample of men who have sex with men in the era of highly active antiretroviral therapy. Sex Transm Dis 2006; 33:250-255.
10. Branson BM, Stekler JD. Detection of acute HIV infection: We can't close the window. J Infect Dis 2012; 205:521-524.
11. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed October 30, 2012.
12. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
13. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191:1403-1409.
14. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis 2008; 198:687-693.
15. Prevalence and awareness of HIV infection among men who have sex with menV21 cities, United States, 2008. MMWR Morb Mortal Wkly Rep 2010; 59:1201-1207.
16. Katz DA, Golden MR, Hughes JP, et al. Acceptability and Ease of Use of Home Self-Testing for HIV Among Men Who Have Sex With Men. 19th Conference on Retroviruses and Opportunistic Infections. Seattle, WA; 2012.
17. Masciotra S, McDougal JS, Feldman J, et al. Evaluation of an alternative HIV diagnostic algorithm using specimens from seroconversion panels and persons with established HIV infections. J Clin Virol 2011; 52(suppl 1):S17YS22.
18. Katz DA, Dombrowski JC, Swanson F, et al. HIV intertest interval among MSM in King County, Washington. Sex Transm Infect 2013; 89:32-37.
19. HIV testing among men who have sex with menV21 cities, United States, 2008. MMWR Morb Mortal Wkly Rep 2011; 60:694-699.
20. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360:1815-1826.
21. Ventuneac A, Carballo-Dieguez A, Leu CS, et al. Use of a rapid HIV home test to screen sexual partners: An evaluation of its possible use and relative risk. AIDS Behav 2009; 13:731-737.
22. Carballo-Dieguez A, Frasca T, Balan I, et al. Use of a rapid HIV home test prevents HIV exposure in a high risk sample of men who have sex with men. AIDS Behav 2012; 16:1753-1760.
23. Katz DA, Golden MR, Stekler JD. Use of a home-use test to diagnose HIV infection in a sex partner: A case report. BMC Res Notes 2012; 5:440.
24. Katz DA, Golden MR, Stekler JD. Point of sex testing: Intentions of men who have sex with men to use home-use HIV tests with sex partners. 2012 National Summit on HIV and Viral Hepatitis Diagnosis, Prevention and Access to Care; Washington, DC; 2012.
25. Porco TC, Martin JN, Page-Shafer KA, et al. Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS 2004; 18:81-88.
26. Sullivan P, Kayitenkore K, Chomba E, et al. Reduction of HIV Transmission Risk and High Risk Sex While Prescribed ART: Results From Discordant Couples in Rwanda and Zambia. 16th Conference on Retroviruses and Opportunistic Infections; Montreal; 2009.
27. Chen M, Rhodes PH, Hall IH, et al. Prevalence of undiagnosed HIV infection among persons aged 9/=13 yearsVNational HIV Surveillance System, United States, 2005-2008. MMWR Morb Mortal Wkly Rep 2012; 61(suppl):57-64.
28. Busch MP, Lee LL, Satten GA, et al. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: Implications for screening of blood and tissue donors. Transfusion 1995; 35:91-97.
29. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: Implications for diagnosis and staging of primary HIV infection. AIDS 2003; 17:1871-1879.
30. Longini IM Jr, Clark WS, Byers RH, et al. Statistical analysis of the stages of HIV infection using a Markov model. Stat Med 1989; 8:831-843.
31. Survival after introduction of HAART in people with known duration of HIV-1 infection. The CASCADE Collaboration. Concerted Action on SeroConversion to AIDS and Death in Europe. Lancet 2000; 355:1158-1159.
32. Chou R, Fu R, Huffman LH, et al. Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: Discrepancies between direct and indirect meta-analyses. Lancet 2006; 368:1503-1515.
33. Vittinghoff E, Douglas J, Judson F, et al. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol 1999; 150:306-311.
34. Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2002;CD003255.